CATEGORIES: Clinical Trials | CMT Summit | Featured | Patient-Focused Research | Pediatrics & CMT | Research

MDA Awards Grant to HNF for Groundbreaking Digital Wearable Study on CMT!

by | Feb 3, 2025 | 0 comments

Exciting news for the Charcot-Marie-Tooth (CMT) community! The Hereditary Neuropathy Foundation (HNF) has been awarded an Advocacy Collaboration Grant from the Muscular Dystrophy Association (MDA) to further its groundbreaking work in CMT research. This funding will drive critical advancements in understanding how CMT affects mobility and quality of life—and we need YOU to be part of it!

As part of this initiative, HNF has partnered with BioSensics™ to conduct a pioneering wearable technology study designed to remotely monitor daily activities and functions of people living with CMT in real-world settings. This study utilizes FDA-registered wearable devices like PAMSys™, which continuously track movement, providing invaluable data that can help researchers and clinicians better understand CMT’s impact.

Why does this matter?

Shaping the Future of CMT Treatment – Real-world data is key to improving therapies and clinical trials.

Improving Patient Advocacy & Research – Your participation helps drive policy changes and better support for the CMT community.

Easy & Non-Invasive – The wearable device collects data seamlessly, requiring little effort from you!

Be a Part of This Game-Changing Study at the CMT Summit!

We are actively seeking participants aged 8-70 to join this important study at the upcoming HNF Clinical Trial Readiness Summit, happening April 24-26 in Nashville, TN. This is your chance to contribute to research, meet leading experts in the field, and connect with others in the CMT community.

Don’t Miss Out – Sign Up Now!

Be a driving force in the future of CMT treatments and research. Register for the HNF Summit and sign up for the wearable tech study today.

Read the Full Press Release
Do you qualify for the Study?
Register for the Summit & Study

Have questions about the summit or wearable study?

Join us on zoom Wednesday, Feb. 27, 2025 anytime between 3:00pm – 4:00pm ET

Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

by | Sep 16, 2014 | , | 2 Comments

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

by | Aug 19, 2014 | , , | 1 Comment

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

by | Jul 7, 2014 | | 4 Comments

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | May 19, 2014 | | 0 Comments

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

by | Feb 28, 2014 | | 0 Comments

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

by | Feb 12, 2014 | | 6 Comments

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

by | Sep 6, 2013 | , | 0 Comments

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news